Aardvark Therapeutics Inc (AARD) Stock Price, Quote & News

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 225 7696

Website: aardvarktherapeutics.com

Address:

4370 La Jolla Village Drive, Suite 1050, San Diego, United States

focafoca99 Aug. 27 at 2:17 PM

$AARD alerts investors to a securities class action alleging false safety claims for ARD-101.

0 · Reply

focafoca99 Aug. 25 at 2:31 PM

$AARD files a securities class action notice for investors to seek recovery.

0 · Reply

11thestate Aug. 24 at 2:11 PM

In the end, $AARD investors were left with the stock down more than 70% across two major disclosures and stuck with their losses. Here’s an update worth your attention: a new case was recently filed against Aardvark Therapeutics over claims that the company overstated the safety of its lead drug ARD-101, including calling it “well-tolerated” while allegedly concealing cardiac safety risks. Check out the latest case updates and learn how to join the case here: https://11th.com/cases/aardvarktherapeutics-investor-suit

0 · Reply

LivermoresGhost Aug. 22 at 7:17 PM

$CVAT Cavitation Technologies has execute a buyout for this company at 35 million $. This translate to 10.8c per share, you can finds this on the company SEC filing. The stock right now trades 3.9c, the buyout is for 10.8c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 10.8c Current sp: 3.9c 270% Return on Investment, Tender will start Monday!!!! https://www.compuserve.com/pf/story/0022/20260817/9811028.htm $PSQH $ISOU $NINE $AARD

1 · Reply

Biotechnicity Aug. 20 at 7:28 AM

$AARD Don’t hold a position here but want to voice a minority opinion holding that SAE’s in healthy subjects is Bullsh*t given that already compromised Prader-Willi patients might not experience the same response. It’s entirely possible that patients with already compromised CVS may, in fact, respond differently. I’m well aware of the historical precedent of caution with respect to healthy patients but scraping a study on that axiom alone seems precipitous. Aardvark will launch the Phase-3 again.

1 · Reply

focafoca99 Aug. 17 at 6:25 PM

$AARD announced a securities class-action deadline for investors on Oct 13.

0 · Reply

MoneyFairyBlessings Aug. 11 at 3:29 PM

$AARD Very bullish here. The volume is impressive considering it does not normally have any volume.

0 · Reply

55X_ROI_Q1_2026 Aug. 2 at 7:52 AM

$AARD $SLS @jfais is a pos short scumbag. $XBI said to sell SlS short +400% ago. "Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe SELLAS is on the verge of such an advance. I have been impressed with the significant potential of the Company's lead product, galinpepimut-S, to successfully treat hematological and solid malignancies through a unique approach of peptide-based immunization against the WT1 oncoprotein," stated Dr. Weber. "I am excited to join the other scientists on the Company's SAB and offer the insights that I have in the area of oncoimmunology research and development.

0 · Reply